Author

Linda Cingolani

BIOLOGIC AGENTS IN IBD PATIENTS AFTER SOLID ORGAN TRANSPLANTATION DO NOT INCREASE THE RATES OF INFECTION OR ADVERSE EVENTS
BIOLOGIC AGENTS IN IBD PATIENTS AFTER SOLID ORGAN TRANSPLANTATION DO NOT INCREASE THE RATES OF INFECTION OR ADVERSE EVENTS

Linda Cingolani  et al.

BIOLOGIC AGENTS IN IBD PATIENTS AFTER SOLID ORGAN TRANSPLANTATION DO NOT INCREASE THE RATES OF INFECTION OR ADVERSE EVENTS
BIOLOGIC AGENTS IN IBD PATIENTS AFTER SOLID ORGAN TRANSPLANTATION DO NOT INCREASE THE RATES OF INFECTION OR ADVERSE EVENTS

SWITCHING FROM ADALIMUMAB ORIGINATOR TO ABP 501 BIOSIMILAR: A MULTICENTRIC NORTH ITALIAN STUDY
SWITCHING FROM ADALIMUMAB ORIGINATOR TO ABP 501 BIOSIMILAR: A MULTICENTRIC NORTH ITALIAN STUDY

Linda Cingolani  et al.

SWITCHING FROM ADALIMUMAB ORIGINATOR TO ABP 501 BIOSIMILAR: A MULTICENTRIC NORTH ITALIAN STUDY
SWITCHING FROM ADALIMUMAB ORIGINATOR TO ABP 501 BIOSIMILAR: A MULTICENTRIC NORTH ITALIAN STUDY

THE ANTI IL-23/IL-12 AGENT USTEKINUMAB IS AN EFFECTIVE AND SAFE INDUCTION THERAPY IN PATIENTS WITH CROHN'S DISEASE REFRACTORY OR INTOLERANT TO ANTI-TNF: A MULTICENTRE ITALIAN STUDY
THE ANTI IL-23/IL-12 AGENT USTEKINUMAB IS AN EFFECTIVE AND SAFE INDUCTION THERAPY IN PATIENTS WITH CROHN'S DISEASE REFRACTORY OR INTOLERANT TO ANTI-TNF: A MULTICENTRE ITALIAN STUDY

Linda Cingolani  et al.

Item 1 - 5 / 5
1